IP strategy for pharma is not just about patents. An understanding of regulatory exclusivity protections is also critical. The protection offered by regulatory exclusivities may extend beyond composition of matter protection for a product and/or cover life cycle management indications awarded an orphan designation. The pharma industry has therefore been watching the progress of the EU pharma
